Atopic dermatitis (AD) is a chronic, inflammatory skin condition with significant patient heterogeneity and links to broader type II inflammatory diseases such as asthma and allergic rhinitis. Understanding disease mechanisms requires precise tools—tissue-specific biomarkers provide quantifiable insights into epidermal and dermal damage, as well as immune cell activity.

Nordic Bioscience’s ProteinFingerPrint Technology™ offers a clinically validated, ECM-focused biomarker platform that enables precise disease characterization, supports targeted therapy development, and facilitates scalable diagnostic solutions. This approach enhances precision medicine by identifying distinct pathological processes and guiding effective, individualized treatment strategies.

Psoriasis is a chronic inflammatory skin disorder marked by excessive extracellular matrix remodeling and heightened immune cell activity, resulting in painful, scaly plaques. Nordic Bioscience’s ProteinFingerPrint Technology™ delivers tissue-specific biomarkers that quantify epidermal and dermal damage, enabling precise assessment of disease activity and progression.

These ECM-based markers support a targeted understanding of psoriasis pathogenesis, improve therapy selection, and provide critical data for clinical trials. Their specificity surpasses broad-spectrum omics approaches, making them integral to advancing precision medicine and individualized treatment strategies in dermatology.

Nordic Bioscience effectively integrates innovative translational models with ProteinFingerPrint Technology™ to translate findings efficiently. By using the same biomarkers throughout various clinical development stages, they create a seamless link between preclinical models and clinical applications. This strategically chosen development pathway significantly boosts the efficiency of drug development pipelines.